Stephens analyst Scott Fidel raised the firm’s price target on Tenet Healthcare to $77 from $64 and keeps an Equal Weight rating on the shares. Q1 performance reflects a return to more normalized levels of consumption for traditional healthcare services as COVID prevalence diminishes and labor pressures ease, says the firm. Updated 2023 guidance, however, implies moderation in top-line growth for the key USPI ASC segment, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $84 from $74 at Truist
- Tenet Healthcare price target raised to $85 from $72 at Raymond James
- Tenet Healthcare price target raised to $84 from $73 at RBC Capital
- Tenet Healthcare price target raised to $105 from $70 at Barclays
- Tenet Healthcare sees FY23 adjusted EPS $4.92-$6.09